THANK YOU FOR SUBSCRIBING
The latest partnership rolls out digitally powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to offer new treatments faster.
FREMONT, CA: Bayer and US-based Recursion Pharmaceuticals, a digital biology company industrializing drug discovery, signs a strategic collaboration agreement. The partnership will use Recursion’s purpose-built artificial intelligence-based drug discovery platform and Bayer’s small molecule compound library and deep expertise to discover and develop new treatments for fibrotic diseases of the lung, kidney, heart, and more. Additionally, Leaps by Bayer, the impact investment arm of Bayer AG, is leading Recursion’s Series D financing with an investment of USD 50 million.
Bayer is driving forward digital transformation in R&D as it believes that digital technologies such as artificial intelligence and machine learning, provide a myriad of novel opportunities to address the complex biology of many diseases and identify new treatments for patients. The collaboration with Recursion enables the company to discover small molecule drug candidates targeting novel biology for the treatment of fibrotic diseases and complements its expertise in cardiovascular research with digital technologies. AI and the use of machine learning methods allow the processing of enormous amounts of data generated by screens and offer unprecedented potential for the discovery of new drug candidates for diseases like fibrotic diseases.
Leaps by Bayer invests in paradigm-shifting innovations in the life sciences, and artificial intelligence might be one of the most intriguing technologies of today. Recursion is a pioneering digitally-powered drug discovery firm to lift biotech research to new horizons with the use of AI and pioneers transformational machine-learning powered drug discovery with the ability to develop curative treatments in the future. Recursion’s drug discovery platform integrates highly automated, wet lab biology experiments as the base for iterative learning through its computational techniques. The purpose-built drug-discovery platform is powered by a proprietary library of images of human cells from several experiments conducted in-house at Recursion and coupled with advanced data.
Under the terms of the agreement, both the parties may initiate more than ten programs with possible development and commercial milestone payments of more than USD 100 million per program plus royalties on future sales.